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Objective. Neonates have a high risk of oxidative stress during anesthetic procedures. The predictive role of oxidative stress
biomarkers on the occurrence of brain injury in the perioperative period has not been reported before. Methods. A prospective
cohort study of patients requiring major surgery in the neonatal period was conducted. Biomarker levels of nonprotein-bound
iron (NPBI) in plasma and F2-isoprostane in plasma and urine before and after surgical intervention were determined. Brain
injury was assessed using postoperative MRI. Results. In total, 61 neonates were included, median gestational age at 39 weeks
(range 31–42) and weight at 3000 grams (1400–4400). Mild to moderate brain lesions were found in 66%. Logistic regression
analysis showed a signiﬁcant diﬀerence between plasma NPBI in patients with nonparenchymal injury versus no brain injury:
1.34 umol/L was identiﬁed as correlation threshold for nonparenchymal injury (sensitivity 67%, speciﬁcity 91%). In the
multivariable analysis, correcting for GA, no other signiﬁcant relation was found with the oxidative stress biomarkers and risk
factors. Conclusion. Oxidative stress seems to occur during anaesthesia in this cohort of neonates. Plasma nonprotein-bound
iron showed to be associated with nonparenchymal injury after surgery, with values of 1.34 umol/L or higher. Risk factors
should be elucidated in a more homogeneous patient group.
1. Introduction
The impact of surgery and anaesthesia on the young infants’
brain is a subject of ongoing debate. Major surgery has been
shown to give a higher risk of death or neurodevelopmental
impairment in a large, retrospective cohort study in very
low-birth-weight infants [1]. Commonly used inhalational
anaesthetics are reported to be neurotoxic in experimental
studies and induce neuronal apoptosis [2, 3]. Studies on the
clinical eﬀect of anaesthetics on the developing brain are
challenging. Infants with major noncardiac congenital anom-
alies requiring neonatal surgery (esophageal atresia, intesti-
nal atresia, anorectal malformation, and gastroschisis) have
an increased risk of a neurodevelopmental delay [4]. These
patients are at risk of oxidative stress due to the anaesthetic
procedure including administration of sevoﬂurane, the frac-
tion of inspired oxygen, and pain, especially since the ten-
dency is to keep them highly saturated during surgery [5].
Fluctuations in blood pressure, arterial CO2, and duration
of anaesthesia pose a risk for the neonatal brain in terms of
developing brain injury [6]. In 63% of patients with noncar-
diac congenital anomalies in this cohort study, brain lesions
were visible on their postoperative MRI [7]. The exact timing
of the brain injury may help to discover the pathogenesis of
these lesions. In this process, biomarkers of oxidative stress
might provide insight into aetiology and pathogenic factors.
To date, very few reported on the role of the anaesthesic pro-
cedure in this patient group. In this study, we hypothesize
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that biomarkers of oxidative stress (i.e., plasma and urinary
F2-isoprostane and plasma nonprotein-bound iron) are
associated with brain injury and aim to clarify the aspects
of oxidative stress during anaesthesia. The association
between perioperative parameters, such as mean arterial
blood pressure, arterial CO2, administration of opioids and
duration of anaesthesia, and biomarkers for neuronal injury,
was investigated.
2. Material and Methods
2.1. Patients. This prospective, cohort study was performed
from January 2014 to December 2015 at the Neonatal
Intensive Care Unit of the Wilhelmina Children’s Hospital
Utrecht, Utrecht, the Netherlands. All eligible newborns
with noncardiac congenital anomalies, requiring major
neonatal surgery, were enrolled. This study was approved
by the Medical Ethical Committee of the University Medi-
cal Center Utrecht. Parents were asked for written informed
consent, in accordance to the principles of the Declaration
of Helsinki (64th WMA General Assembly, Fortaleza, Brazil,
October 2013).
Exclusion criteria consisted of critical cardiac congenital
malformations, major congenital anomalies of the central
nervous system, and insuﬃcient Dutch language proﬁciency
of the parents.
3. Methods
3.1. Biomarkers. Heparinized blood samples of 1ml were
drawn from the indwelling peripheral arterial catheter and
inserted for clinical purposes. These samples were centri-
fuged immediately, to obtain platelet-poor plasma, and
butylated hydroxytoluene (BHT) 1% w/v in methanol (5 μl
per ml of plasma) was added to prevent the in vitro lipid
peroxidation [8]. Urine samples of 4ml were collected from
already inserted urinary catheters or noninvasively from a
gauze placed in the infants’ diaper. Six time points were cho-
sen: within 24 hours prior to surgery; immediately after sur-
gery; and 6, 24, and 72 hours after surgery for measurement
of biomarkers of neuronal injury (Figure 1). Blood and urine
samples were stored in a refrigerator at −80°C until analysis.
Plasma levels of NPBI were detected by high-performance
liquid chromatography (HPLC) as described by Paﬀetti
et al. [9] using an HPLC system consisted of quaternary
pumps, vacuum degassers, thermostated autosampler, DAD
detector, and ﬂuorimeter detector (Agilent 1100 series).
The method is based on preferential chelation of NPBI by
a large excess of the low-aﬃnity ligand of nitrilotriacetic
acid (NTA).
Determination of F2-isoprostanes in plasma and urine
was described by Casetta et al. [10]. The method was centered
around an API 4000 Tandem Mass Spectrometer (AB Sciex,
Toronto, Canada) equipped with an electrospray ionization
(ESI) probe on the Turbo-V source. The chromatographic
conﬁguration was an Agilent 1200 stack. The chromato-
graphic conﬁguration was an Agilent 1200 stack, which
included a binary pump, a thermostated well-plate autosam-
pler (kept at 8°C), and a column oven.
The chromatography separation was carried out on a
Dionex Acclaim C18-120 3um 2× 100mm, maintained at
30°C, and ﬂowed at a rate of 300 μl/min by a mixture of an
aqueous solution of acetic acid at 0.3% (eluent A) and
acetonitrile (eluent B) according to the following gradient
program. Upon injection, the eluent composition was main-
tained at 25% of B for 1′ and then moves up to 90% in 4′. Sub-
sequently, the concentration of eluent B reaches 100% for 1′.
The equilibration step was performed at 25% of B for 4′.
Total chromatographic run was 10 minutes.
For measurements, the tandem mass spectrometer has
been run in multiple reaction monitoring (MRM) with the
electrospray source operating in negative ion mode and by
exploiting the transition m/z 353.3> 193.2 for F2-isopros-
tanes and 357.3> 197.2 for the isotopically-labeled form used
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Figure 1: Time distribution sampling points.
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as internal standard (d4–8-iso PGF2α, Cayman Chemical Co.,
Ann Arbor, MI, USA) [11].
3.2. Neuroimaging. A postoperative MRI was performed on a
3.0 Tesla whole-body Achieva system (Philips Medical
Systems, Best, the Netherlands) as part of routine clinical
care. The scanning protocol included T1-, T2-, diﬀusion,
and susceptibility weighted images.
3.3. Data. Obstetric and neonatal data, perioperative data, as
well as details on anaesthetic and surgical management were
collected from patient charts.
3.4. Statistical Analysis. Statistical procedures were per-
formed using IBM SPSS statistics software package (IBM®
SPSS Statistics version 20, IBM Corp. Armonk, NY, USA,
and R statistical computing) [12]. Data are presented as
mean± standard deviation (SD) or as median and range
when indicated. Comparison of biomarker levels before and
after surgery was performed using the Wilcoxon signed-
rank test and the Bonferroni post hoc correction for multiple
testing. The Mann– Whitney U test was performed to com-
pare biomarker levels and presence of brain injury. A multi-
variable regression analysis was performed using the
cumulative concentration of biomarker levels in the ﬁrst 60
hours after surgery. Parameters investigated were gender,
type of congenital anomaly, endoscopic procedure, and the
occurrence of parenchymal injury, after correcting for gesta-
tional age. Receiver operating characteristic curves (ROC)
were calculated at diﬀerent time points from T1 to T4, in
order to detect the best time point correlating with damage.
4. Results
Of the 84 patients admitted to the NICU between January
2014 and December 2015 and who underwent major surgery
in the neonatal period, parents of 73 neonates were
approached and asked for consent of their infant to partici-
pate in the study. Exclusion criteria consisted of emergency
surgery (n = 4), absence of one of the parents (n = 3), insuﬃ-
cient Dutch language proﬁciency (n = 3), or diagnosis made
during surgery (n = 1). In 61 of these 73 neonates, parental
informed consent was given. Clinical data are presented in
Table 1 (Supplemental Table 1 available online at https://
doi.org/10.1155/2017/2728103 and Supplemental Table 2.
Anesthetics during surgery). Figure 1 shows the time distri-
bution of each sampling point.
4.1. Oxidative Stress Biomarkers. Plasma and urinary levels of
F2-isoprostane and plasma NPBI were not signiﬁcantly dif-
ferent before surgery in comparison to values after surgery
(T0 versus T1–T4, Wilcoxon signed-rank test with post hoc
Bonferroni, p > 0 3) (Figure 2) (Supplemental Table 2).
4.2. Brain Lesions. Parenchymal and/or nonparenchymal
brain lesions were found in 66% of 58 postoperative MRI
scans (Table 2 and Figure 3). In 18 neonates, a combination
of parenchymal and nonparenchymal injury was visible. In
51% of the neonates, parenchymal injury was present and
55% of these lesions were visible on the diﬀusion weighted
images (DWI), which indicates timing of the injury to be in
the perioperative period. The cumulative concentration of
plasma F2-isoprostane of patients with no brain injury
showed signiﬁcantly lower levels than patients with paren-
chymal injury (Mann–Whitney U test, U=11.0, p < 0 01, r
= −0 70, Figure 4), indicating higher concentrations of F2-
isoprostane in patients with brain injury.
4.3. Multivariable Linear Regression. In the multivariable
analysis, using the cumulative concentration starting directly
after surgery to 60 hours after surgery for each biomarker,
correcting for GA, none of the potentially inﬂuencing factors
showed a signiﬁcant linear relation with plasma and urinary
F2-isoprostane or plasma NPBI. Parameters investigated
consisted of gender, type of congenital anomaly, endoscopic
procedure, and the occurrence of parenchymal injury
(Figure 4). This indicates that after correcting for gestational
age, the absence or presence of brain injury did not inﬂuence
the overall concentrations of the oxidative stress biomarkers
in the perioperative period.
4.4. ROC Curve Analysis. A logistic regression was performed
for each time point. A signiﬁcant diﬀerence in plasma NPBI
was found between patients with nonparenchymal injury
Table 1: Clinical data.
n = 61
Gestational age (weeks) 38.9 (30.9–41.6)
Male, n (%) 36 (59%)
Birth weight (grams) 3000 (1405–4430)
Birth weight z-score −0.25 (−2.1–1.9)
Small for gestational age, n (%) 2 (3%)
Preterm, n (%) 15 (25%)
Apgar score 1 minute 9 (2–10)
Apgar score 5 minutes 10 (2–10)
Postnatal age in days at time of surgery 2 (0–8)
Postnatal age in hours at time of surgery 39.9 (2–184)
Surgery
Thoracoscopy, n (%) 18 (30%)
Laparoscopy, n (%) 16 (26%)
Laparotomy, n (%) 23 (38%)
Duration surgery (minutes) 115 (23–475)
Duration anaesthesia (minutes) 189 (63–563)
Medication during anaesthesia
Sevoﬂurane, n (%) 60 (98%)
Isoﬂurane, n (%) 1 (2%)
Sufentanil, n (%) 60 (98%)
Propofol, n (%) 14 (23%)
Morphine, n (%) 17 (28%)
Caudal analgesia, n (%) 13 (21%)
Suxamethonium, n (%) 1 (2%)
Atracurium, n (%) 51 (84%)
Rocuronium, n (%) 9 (15%)
Data displayed in median (range) or indicated otherwise.
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Figure 2: Perioperative data of oxidative stress biomarkers. (a) Data of plasma NPBI at each time point. Dotted line indicates 2.3 umol/L
NPBI, and normal values of plasma NPBI are below this cutoﬀ value. (b) Data of plasma F2-isoprostane at each time point. Dotted
line indicates 60 pg/mL F2-isoprostane, and normal values of plasma F2-isoprostane are below this cutoﬀ value. (c) Data of urinary
F2-isoprostane at each time point. Dotted line indicates 1.3 pg/mg creatinine F2-isoprostane, and normal values of urinary F2-isoprostane
are below this cutoﬀ value.
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(78.5%) and patients with no brain injury after anaesthesia.
The results indicate plasma NPBI at 72 hours after surgery
as the best early predictor for nonparenchymal injury. The
determination of NPBI levels at 72 hours after surgery allows
in diﬀerentiating neonates having nonparenchymal brain
injury from no brain injury: AUC 78.5% (95% conﬁdence
interval: 0.595–0.975), with 66.7% speciﬁcity and 90.9%
sensitivity (Figure 5). The threshold 1.34μM/l was identiﬁed
as predictive value for having nonparenchymal injury. A
predictive threshold value at one speciﬁc time point could
not be identiﬁed for F2-isoprostane.
5. Discussion
This study investigated oxidative stress biomarkers in neo-
nates undergoing neonatal surgery for noncardiac congenital
anomalies. In this cohort, 66% of the neonates had mild to
moderate brain lesions visible on their postoperative MRI.
A combination of parenchymal and nonparenchymal injury
was found in 30% of the infants. In the total patient cohort,
after correcting for gestational age, perioperative biomarker
concentrations of F2-isoprostane and NPBI were not corre-
lated to perioperative brain injury. In the ROC curve analysis,
assessing the subgroups no brain injury, parenchymal and
nonparenchymal brain injury at each time point, and oxida-
tive stress seems to occur as a consequence of anaesthesia.
This was shown by elevated levels of NPBI in plasma and uri-
nary F2-isoprostane after surgery in patients with parenchy-
mal injury in comparison to patients with no brain injury.
In addition to that, the level of 1.34 umol/L plasma NPBI
was identiﬁed as risk threshold for nonparenchymal injury.
Despite the bias related to heterogeneity, this study points
out that these neonates are at risk of oxidative stress during
the anaesthetic procedure.
There is no previous literature available on biomarkers in
patients with noncardiac congenital anomalies requiring
surgery. This could be explained by the fact that patients with
congenital malformations are structurally excluded from
trials. However, biomarkers of neuronal injury might be of
great value in this vulnerable group of patients.
The hypothesis was to ﬁnd an increase in biomarker
values after surgery in comparison to preoperative values.
The basal level of oxidative stress before surgery was reported
for the ﬁrst time. Interestingly, the values of F2-isoprostane at
baseline—before surgery—were low, in comparison to the
ﬁndings of Comporti et al. Newborns in this study had values
between 50–150 pg/ml after birth, and blood samples were
obtained from the umbilical vein. Our results show a median
F2-isoprostane of 30 pg/ml creatinine at baseline, which is
drawn from the arterial catheter at a median age of two days.
Apparently, the oxidative stress at birth caused by the transi-
tion from a low oxygen pressure in utero to a relatively high
oxygen pressure after birth was resolved [19].
Oxidative stress is a unifying term for the end product of
several diseases, which can be produced by free radicals.
Biomarkers are deﬁned as indicators of normal processes or
measures of pathological processes [13]. Free radicals dam-
age the endothelial cell and cause inﬂammatory reactions
and brain cell damage, which can be evaluated by an
increased level of nonprotein-bound iron. NPBI has been
proven to be a predictive biomarker of neonatal brain dam-
age in preterm infants [14]. This biomarker seems to play a
pivotal role in identifying neonates at risk of brain damage.
F2-isoprostanes, discovered by Morrow et al, are a product
of free radical-induced injury by peroxidation of lipids. This
biomarker is formed via nonenzymatic peroxidation of poly-
unsaturated fatty acids mediated by free radical production
[13]. This peroxidation of arachidonic acid is produced by a
noncyclooxygenase mechanism [15] and is a noninvasive
method to monitor lipid peroxidation in vivo. An increase
of F2-isoprostane in plasma and urine occurs after hypoxic-
ischaemic brain injury and reperfusion [16] and predicts
the risk of having brain injury. Previous studies have shown
that F2-isoprostane is a reliable and chemically stable bio-
marker [17, 18]. Importantly, it is previously described that
plasma F2-isoprostane levels are inversely correlated with
gestational age [19]. This is also the case in healthy infants,
Friel et al. found an increased level of F2-isoprostane in a
cohort of 12 infants at the age of one month [5]. Further-
more, lipid exposure to high concentrations of NPBI also
leads to the formation of isoprostanes.
Reactive oxygen species (ROS) are known to cause oxida-
tive stress in the newborn infant, leading to damage to cell
structures like lipids and membranes [5, 20, 21]. Free radical
oxidative damage in the newborn is involved in diseases like
retinopathy of prematurity, bronchopulmonary dysplasia,
necrotizing enterocolitis, and patent ductus arteriosus [21].
In addition, the developing brain of the neonate, with its high
concentration of polyunsaturated fatty acids, is highly sus-
ceptible to hypoxia and hyperoxia [22]. These pathological
circumstances cause oxidative stress reactions, in particular
in the neonate with their immature antioxidant defenses
[23]. White matter is selectively injured, since the developing
oligodendrocyte is the main target of oxidative stress in
hypoxia-ischaemia and systemic inﬂammation [22, 24].
Brain injury has previously been described in the group of
patients with cardiac congenital anomalies undergoing major
surgery [25]. Our results show a high incidence of mild to
moderate brain lesions in infants with noncardiac congenital
anomalies as well.
The sensitivity of the rapidly developing brain of the neo-
nate undergoing major surgery to brain injury is threefold.
First, the developing brain tissue is sensitive to free radicals.
ROS cause oxidative stress [20], in particular, in newborns
with their reduced enzymatic and nonenzymatic antioxidant
defense [21]. Neonates undergoing surgery are exposed to
Table 2: Incidence of brain injury.
Brain injury n∗
No injury 20
Parenchymal injury 13
Nonparenchymal injury 7
Parenchymal and nonparenchymal injury 18
∗MRI was not available in three patients: one was declined by the parents,
one had a preoperative MRI scan only, and one patient was diagnosed with
Down’s syndrome.
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(a) (b)
(c) (d)
(e) (f)
Figure 3: Examples of parenchymal and nonparenchymal brain injury. (a) Coronal T1-weighted image: cortical infarction and subdural
haemorrhage; (b) coronal T1-weighted image: white matter lesion; (c) coronal T1-weighted image: white matter lesion; (d) susceptibility
weighted image: multiple punctate cerebellar lesions; (e) diﬀusion-weighted image: thalamic infarction; (f) susceptibility weighted image:
cerebellar haemorrhage.
6 Disease Markers
ﬂuctuating fractions of inspired oxygen. During induction of
anaesthesia, an increased supply of oxygen is administered,
to prevent hypoxia during intubation, which enhances the
risk of free oxygen radicals. Secondly, inhalational anaes-
thetics are thought to cause neurotoxic eﬀects in the develop-
ing newborn brain [2, 26, 27]. The anaesthetic causes an
increase in apoptosis, an impaired neurogenesis, and neuro-
inﬂammation in animal experimental studies [28]. Third,
cerebral perfusion is at risk due to immature cerebral autore-
gulatory ability in preterm infants or a loss of cerebral auto-
regulation caused by sevoﬂurane anaesthesia [29]. Presence
or absence of autoregulatory ability can be determined by
blood pressure and cerebral oxygenation, measured by
near-infrared spectroscopy [30]. In case of pressure-passive
perfusion, ﬂuctuations in respiratory and cardiovascular
parameters pose a risk for cerebral saturation and perfusion.
Maintenance of cerebral blood ﬂow is critical to ensure ade-
quate oxygenation of the brain.
This study has several limitations. First, with the use of
F2-isoprostane only, a speciﬁc type of brain damage was
investigated, involving the prostaglandin metabolism. The
second limitation is that our cohort consists of a heteroge-
neous patient group. In order to solve this problem, each
patient is used as their own control, with the baseline mea-
surement before surgery. Furthermore, the bias consisted of
diﬀerences in gestational age, weight, diﬀerent surgical tech-
niques, and diﬀerences in administered dose of anaesthesia
and pain medication. The strength of this study, however, is
that it is the ﬁrst study to investigate these biomarkers in neo-
nates with noncardiac congenital anomalies, at multiple time
points, in combination with the use of MRI. Also, the clinical
use of these biomarkers is investigated in this prospective
study where cerebral monitoring is applied in the periopera-
tive period as well. The combination of biomarkers and MRI
oﬀers the opportunity to identify neonates at risk of brain
injury more precisely, which might be of great value to
develop tailored therapy and preventive measures for brain
injury in the future.
6. Conclusion
Despite the bias related to heterogeneity of the study group,
our results showed a risk of oxidative stress during anaesthe-
sia in neonates.
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Figure 5: Receiver operating characteristic (ROC) curve analysis for
NPBI at 72 hours after surgery. The area under the curve indicates
that NPBI at 72 hours after surgery allows to diﬀerentiate neonates
with nonparenchymal injury from no injury. The area under the
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